RT Journal Article
SR Electronic
T1 Predictors of Response to Cardiac Resynchronization Therapy in Pediatric and Congenital Heart Disease Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.12.24318957
DO 10.1101/2024.12.12.24318957
A1 Chubb, Henry
A1 Mah, Douglas
A1 Shah, Maully
A1 Lin, Kimberly Y
A1 Peng, David
A1 Hale, Benjamin W
A1 May, Lindsay
A1 Etheridge, Susan
A1 Goodyer, William
A1 Ceresnak, Scott R
A1 Motonaga, Kara S
A1 Rosenthal, David N
A1 Almond, Christopher S
A1 McElhinney, Doff B
A1 Dubin, Anne M
YR 2024
UL http://medrxiv.org/content/early/2024/12/13/2024.12.12.24318957.abstract
AB Background Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection fraction (EF). However, the identification of optimal responders is challenging.Objective To identify predictors of response to CRT in children and CHD patients at 5 large quaternary referral centers.Methods Patients were <21 years or had CHD; had SVEF <45%; symptomatic heart failure; and significant electrical dyssynchrony prior to CRT. Primary outcome was defined as an ordinal response at 6/12months: (1) Improved EF [≥5%], (2) Unchanged SVEF, (3) Worse SVEF. Secondary outcome utilized a propensity score-matched control cohort. Response to CRT was defined using longitudinal trajectory of SVEF up to latest follow-up.Results In total, 167 eligible CRT recipients were identified across the 5 centers. 150 had comprehensive data at 6/12months: 96(64%) with improved SVEF, 26(17%) unchanged, 28(19%) worsened. Mean increase in SVEF was 11% [IQR 3-21%]. On univariable ordinal regression, lower SVEF (p=0.013), biventricular circulation (p=0.022), systemic LV (p=0.021), and conduction delay to lateral wall of SV (p=0.01) were associated with positive response.For assessment of secondary outcome, 324 controls were identified. Mean follow-up 4.2(±3.7) yrs. Almost all subgroups demonstrated improved SVEF trend with CRT, except those with systemic RV (p=0.69) or without prior single site pacemaker (p=0.20).Conclusion CRT in children and CHD patients frequently results in an improvement in SVEF. Those with lower SVEF, conduction delay to lateral wall of the SV and those with systemic LV are most likely to respond.Condensed Abstract Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection fraction (EF). However, the identification of optimal responders is challenging.In this multicenter study, pediatric and CHD CRT recipients with heart failure and EF<45% were identified. The primary outcome was change in EF at 6/12months. Those with lower baseline SVEF, conduction delay to lateral wall of the SV and/or systemic LV were most likely to respond to CRT. When compared to propensity score-matched controls, the CRT groups also demonstrated a significantly better long-term EF trajectory.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis was a retrospective studyFunding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Stanford University, IRB-45389I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymized data is available on reasonable request following publication of the manuscriptCHDCongenital Heart DiseaseCRTCardiac Resynchronization TherapyDCMDilated CardiomyopathyEFEjection FractionHFHeart FailureHRHazard RatioICDImplantable Cardioverter DefibrillatorLVLeft VentricleNYHANew York Heart AssociationPSMPropensity Score-MatchQRSdQRS DurationRVRight VentricleSVSystemic Ventricle